Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Non–Small-Cell Lung Cancer Patients

Background: Radon gas is the leading cause of lung cancer in the nonsmoking population. The World Health Organization (WHO) recommends indoor concentrations of < 100 Bq/m³. Several molecular alterations have been described in non–small-cell lung cancer (NSCLC), mainly in nonsmokers, with no risk factors identified. We studied the role of indoor radon in NSCLC patients harboring specific driver alterations. Conclusion: The median indoor radon concentration was above the WHO recommendations, with no differences between EGFR, ALK, and BRAF patients. Concentrations above the WHO recommendations were most common with ALKr and BRAFm. These findings should be validated in larger studies. READ ARTICLE

Clinical Lung Cancer DOI:10.1016/j.cllc.2019.04.009

Authors: Laura Mezquita, Amparo Benito, Alberto Ruano-Raviña, Javier Zamora,Maria Eugenia Olmedo, Pablo Reguera, Ainhoa Madariaga, María Villamayor, Silvia Patricia Cortez, Luis Gorospe, Almudena Santón, Sagrario Mayoralas, Raúl Hernanz, Alberto Cabañero, Edouard Auclin, Alfredo Carrato, Pilar Garrido